MDS Current Trials UK

We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.

Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses. If you'd like more information about what a clinical trial is and how it is conducted, please go to this section or download our Clinical Trials factsheet.

Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly. However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.

In addition, here you will find a list of clinical trials which are still running but are closed to recruitment. 

All the trials listed in this page have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for her continuous work in updating this listing.

Learn more about the latest MDS research
Research FOR Patients

MDS Clinical Trials

Luspatercept in long term follow-up

Luspatercept in long term follow-up
  1. SUB-TYPE OF MDS:Low risk MDS patients who have participated in other Luspatercept clinical trials
  2. SEVERITY OF MDS: IPSS-R Very Low, Low or Intermediate Risk MDS
  3. NAME OF DRUG: Luspatercept
Read full story

UCART123 – Clinical Trial Open to Recruitment

UCART123 – Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS:Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML), including patients with CD123 positive AML secondary to MDS
  2. SEVERITY OF MDS: AML
  3. NAME OF DRUG: UCART targeting CD123 positive leukaemia cells
Read full story

RFUSIN2-AML1 – Clinical Trial Open to Recruitment

RFUSIN2-AML1 – Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS:Patients AML (acute myeloid leukaemia) who fail to enter morphological remission or have persistence of cytogenetic abnormality following intensive combination chemotherapy at day+100 post-transplant
  2. SEVERITY OF MDS: AML
  3. NAME OF DRUG: Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) that express
    B7.1 (CD80) and IL-2 (AML cell vaccine)
Read full story

ACE-536-MDS-002 (Luspatercept)

ACE-536-MDS-002 (Luspatercept)
  1. SUB-TYPE OF MDS:Lower Risk MDS patients who require red cell transfusions but have not received Erythropoietin
  2. SEVERITY OF MDS: IPSS-R Very Low, Low or Intermediate Risk MDS
  3. NAME OF DRUG: Luspatercept
Read full story

PANTHER: Clinical Trial Open to Recruitment

PANTHER: Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS:Higher risk MDS, CMML, low blast count AML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Azacitidine, Pevonedistat
Read full story

BRIGHT: Clinical Trial Open to Recruitment

BRIGHT: Clinical Trial Open to Recruitment
  1. SUB-TYPE OF MDS:Previously untreated higher-risk MDS, AML or CMML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Glasdegib, Azacitidine
Read full story
Free donations by shopping